

Meng Li, ScM

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11524255/publications.pdf>

Version: 2024-02-01

11
papers

77
citations

1937685

4
h-index

1474206

9
g-index

11
all docs

11
docs citations

11
times ranked

133
citing authors

#	ARTICLE	IF	CITATIONS
1	Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2022, 40, 623-631.	3.3	3
2	A Pragmatic Guide to Assessing Real Option Value for Medical Technologies. <i>Value in Health</i> , 2022, 25, 1878-1884.	0.3	4
3	Managing high-priced biologic agents: challenges and potential solutions. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 411-414.	0.9	0
4	Real-world evidence for option value in metastatic melanoma. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1-10.	0.9	1
5	Modeling the Ex Post Real Option Value in Metastatic Melanoma Using Real-World Data. <i>Value in Health</i> , 2021, 24, 1746-1753.	0.3	5
6	Cancer history, insurance coverage, and cost-related medication nonadherence in Medicare beneficiaries, 2013-2018. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1750-1756.	0.9	1
7	Medicare Beneficiaries, Especially Unsubsidized Minorities, Struggle to Pay for Prescription Drugs: Results from the Medicare Current Beneficiary Survey. <i>Journal of General Internal Medicine</i> , 2020, 35, 1334-1336.	2.6	1
8	Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 400-406.	0.9	10
9	How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma. <i>Value in Health</i> , 2019, 22, 777-784.	0.3	14
10	Do cancer treatments have option value? Real-world evidence from metastatic melanoma. <i>Health Economics (United Kingdom)</i> , 2019, 28, 855-867.	1.7	15
11	Using Performance-Based Risk-Sharing Arrangements to Address Uncertainty in Indication-Based Pricing. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 1010-1015.	0.9	23